보고서 요약(국문)

개요
전 세계 시겔라 백신 파이프라인 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
시겔라 백신은 시겔라균에 의해 발생하는 설사 및 이질을 예방하기 위해 개발된 백신입니다. 시겔라 백신 개발은 항생제 사용 감소 및 그에 따른 항생제 내성 발생 억제에 간접적인 영향을 미칠 수 있으므로 공중 보건에 중요한 목표입니다.
시겔라균에는 네 가지 종이 있으며, 이 중 세 종은 여러 혈청형을 가지고 있습니다. 이처럼 다양한 시겔라 혈청형은 면역 보호가 주로 혈청형 특이적이기 때문에 백신 개발에 어려움을 초래합니다. 이질균(Shigella flexneri)은 전 세계적으로, 특히 저소득 국가에서 가장 중요한 종으로, 15가지 혈청형으로 구성되어 있으며, 그중 가장 흔한 것은 S. flexneri 2a이고, 그 다음으로 3a와 6이 흔합니다.
이질균(Shigella sonnei)은 단 하나의 혈청형만 가지고 있으며, 산업 발전이 진행 중인 국가에서 우세한 종입니다. 이질균(Shigella dysenteriae)은 15가지 혈청형을 가지고 있으며, 그중 가장 중요한 것은 이질균 1형으로, 21세기에 들어서면서 사라진 것으로 보이는 높은 치사율의 유행성 발병을 일으켰습니다. 이질균(Shigella boydii)은 19가지 혈청형을 가지고 있으며, 이질 사례의 소수를 차지하며 주로 남아시아에서 발견됩니다.

시장 동향: 성장 동인 및 제약 요인
새로운 백신 파이프라인
효과가 뛰어나고 안전한 이질 백신 개발은 중대한 성과가 될 것이지만, 이미 포화 상태인 예방 접종 일정과 다른 여러 경쟁적인 치료법들 속에서 백신 자체만으로는 판매가 저절로 이루어지지 않을 것입니다. 백신 권고, 구매 및 채택에 필요한 정치적 의지와 풀뿌리 운동을 촉진할 수 있는 설득력 있는 공중 보건적 가치 제안이 있는지 여부를 판단하기 위한 연구가 여전히 필요합니다.
시장 동향: 제약 요인
백신 부작용은 예측 기간 동안 시장 성장을 저해하는 주요 요인 중 하나입니다. 부작용으로는 주사 부위의 통증이나 부기, 발열, 보챔, 식욕 부진, 피로, 구토 등이 있습니다. 인플루엔자 생백신의 경우, 구토, 근육통, 발열, 인후통, 기침 등이 발생할 수 있습니다. 이러한 부작용은 시장 성장을 제한하는 요인입니다.
세분화 분석
전 세계 이질 백신 파이프라인은 백신 유형, 연령대, 최종 사용자 및 지역별로 세분화됩니다. 백신 유형 부문에서 생백신은 시장 점유율의 약 42.2%를 차지했습니다.
생백신은 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 생백신은 병원체의 약화된 형태를 이용하여 제조됩니다. 이질균 백신의 경우, 생균 약독화 균주가 사용됩니다. 이러한 약독화 균주는 야생형 또는 자연 발생 이질균 균주에 비해 독성이 약해지도록(백신을 유발할 수 있는 능력이 약해지도록) 변형되었습니다.

예를 들어, 2022년 10월 12일 clinicaltrials.gov에 따르면, 미국 국립알레르기감염병연구소(NIAID)는 건강한 성인을 대상으로 생균 약독화 이질균 백신 WRSs2의 안전성, 반응성 및 면역원성을 평가하고 이질균 53G 감염 모델에서의 효능을 확인하기 위한 이중맹검 위약 대조 무작위 2상 임상시험을 시작했으며, 현재 2상 시험이 진행 중이고 2024년 7월까지 연구가 완료될 것으로 예상됩니다.
지역 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 진행 중인 임상시험, 개선된 의료 인프라, 연구 개발 활동 및 다수의 생명공학 기업 등의 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다. 제품 개발 및 백신 제품 승인은 예측 기간 동안 이 지역이 가장 높은 시장 점유율을 차지하는 데 도움이 됩니다.
예를 들어, clinicaltrial.gov에 따르면 2022년 9월 29일 메릴랜드 대학교 볼티모어 캠퍼스는 장독소 생성 대장균 항원을 발현하는 약독화 시겔라 플렉스네리 2a 생백신 벡터 프로토타입인 CVD 1208S-122의 경구 투여 안전성, 내약성 및 면역원성 연구를 시작했습니다. 이 임상 시험은 현재 1상 단계에 있으며 미국에서 진행되고 있으며 2024년 9월까지 완료될 것으로 예상됩니다.
COVID-19 영향 분석
COVID-19가 시겔라 백신에 미치는 영향에 대한 정보는 제한적입니다. 그러나 기존의 COVID-19 부스터 백신은 바이러스에 대한 상당한 보호 효과를 제공할 것으로 예상됩니다. 이질 백신 개발은 항생제 내성을 유발하고 선형 성장 둔화를 통해 경제적 영향을 미치기 때문에 공중 보건에 중요한 목표입니다.
시장 세분화
백신 유형별
• 생백신
• 불활화 백신
• 전세포 불활화 백신
• 서브유닛 불활화 백신
• 접합 백신
• 기타
연령대별
• 영유아
• 어린이
최종 사용자별
• 병원
• 진료소
• 비정부기구(NGO)
• 예방접종 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
이질균 백신 파이프라인 시장의 주요 글로벌 기업으로는 LimmaTech Biologics AG, Eveliqure Biotechnologies GmbH, Zhi Fei Biological, Vaxcyte, Inventprise 등이 있습니다.
주요 개발 사항
 2023년 7월, GSK는 LimmaTech Biologics에 이질균 백신 후보 물질의 라이선스를 부여하여, 스위스 바이오테크 기업인 LimmaTech Biologics가 이 4가 생체접합체 임상시험용 백신을 추가 개발하고 최종적으로 상용화할 수 있는 권리를 확보했습니다. LimmaTech는 이 4가 백신 후보 물질에 대한 1/2상 임상시험을 완료하고 올해 안에 연구 결과를 발표할 예정입니다.
 2020년 11월, Eveliqure는 이질균 및 ETEC에 대한 임상 단계 백신 후보 물질의 주요 전임상 데이터를 발표했습니다.
보고서 구매 이유

• 백신 유형, 연령대, 최종 사용자 및 지역별로 세분화된 글로벌 이질균 백신 파이프라인 시장을 시각화하고 주요 상업적 자산과 기업을 파악하기 위해.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.
• 모든 부문을 포함한 다양한 시겔라 백신 파이프라인 시장 수준 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 백신 정보를 담은 엑셀 파일 형태의 제품 맵핑 자료를 제공합니다.

글로벌 시겔라 백신 파이프라인 시장 보고서는 약 46개의 표, 56개의 그림, 165페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Shigella Vaccines Pipeline Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
A Shigella vaccine is a vaccine designed to prevent shigellosis, a Vaccine caused by the shigella bacteria that can lead to moderate-to-severe diarrhoea and dysentery. The development of a Shigella vaccine is an important goal for public health, as it could have indirect effects on reducing the use of antibiotics and the consequent emergence of antimicrobial resistance.
There are four species of shigella, and three of these have multiple serotypes. This large number of Shigella serotypes presents a challenge for vaccine development since immunologic protection is largely serotype-specific. Shigella flexneri is the most important species globally, particularly in low-income countries, and consists of 15 serotypes, the most common of which is S. flexneri 2a, followed by 3a and 6.
Shigella sonnei has just one serotype and is the dominant species in countries that are undergoing industrial development. Shigella dysenteriae has 15 serotypes, the most significant being Shigella dysenteriae type 1, which was responsible for epidemic outbreaks with high-case fatality rates that seem to have disappeared in the 21st century. Shigella boydii, which has 19 serotypes, is responsible for a small minority of shigellosis cases and is mainly detected in South Asia.
Market Dynamics: Drivers and Restraints
Emerging vaccine pipeline
The development of highly effective and safe shigella vaccines would be a major accomplishment, but these vaccines will not sell themselves in the context of a crowded immunization schedule and many other competing interventions. There is still work to be conducted to determine if there is a compelling public health value proposition that can help stimulate the political will and grassroots advocacy often necessary for vaccine recommendations, purchase, and adoption.
Market Dynamics: Restraint
Side effects of vaccines are one the key factors that hamper the market growth during the forecast period. Some of the side effects include soreness or swelling where the shot was given, fever, fussiness, loss of appetite, tiredness, and vomiting. In the case of Influenza live vaccine, vomiting, muscle aches, fever, sore throat, and cough are other possible side effects. These side effects are limiting the market growth.
Segment Analysis
The global shigella vaccine pipeline is segmented based on vaccine type, age group, end-user and region.
The live attenuated vaccines from the vaccine type segment accounted for approximately 42.2% of the market share
The live attenuated vaccines from the vaccine type segment accounted for approximately 42.2% and it is expected to be dominated during the forecast period. Live attenuated vaccines are designed using weakened or attenuated forms of the pathogen. In the case of Shigella vaccines, live attenuated strains of the bacteria are used. These attenuated strains have been modified so that they are less virulent (less capable of causing Vaccine) compared to the wild-type, or naturally occurring, strains of Shigella.
For instance, according to clinical trails.gov on October 12, 2022, National Institute of Allergy and Infectious Vaccines (NIAID) started a clinical study on A Double-Blind Placebo-Controlled Randomized Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. sonnei 53G in Healthy Adults where it is currently under Phase 2 trials and estimated to complete its studies by July 2024.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors like ongoing clinical trials, improved healthcare infrastructure in this region, research and development activities and a large number of biotechnological companies. The development of products and approval of vaccine products helps this region to have the highest market share during the forecast period.
For instance, according to clinicaltrial.gov on September 29, 2022, the University of Maryland, Baltimore started a clinical studies on Study of the Safety, Tolerability, and Immunogenicity of Oral Doses of CVD 1208S-122, a Prototype Attenuated Shigella Flexneri 2a Live Vector Expressing Enterotoxigenic Escherichia Coli Antigens which is currently under phase 1 and this clinical trials are taking place in United States and studies are estimated to complete by September 2024.
COVID-19 Impact Analysis
There is limited information on the impact of COVID-19 on Shigella vaccines. However, existing COVID-19 booster vaccines are expected to provide reasonable protection against the virus. The development of a Shigella vaccine is an important goal for public health, as shigellosis drives antimicrobial resistance and leads to economic impact through linear growth faltering
Market Segmentation
By Vaccine Type
• Live Attenuated Vaccines
• Inactivated Vaccines
• Whole-cell inactivated vaccines
• Subunit inactivated vaccines
• Conjugate Vaccines
• Others
By Age Group
• Infants
• Childrens
By End User
• Hospitals
• Clinics
• Non-Governmental Organizations (NGOs)
• Vaccination Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the shigella vaccine pipeline market include LimmaTech Biologics AG, Eveliqure Biotechnologies GmbH, Zhi Fei Biological, Vaxcyte, Inventprise and among others.
Key Developments
 In July 2023, GSK licensed out its Shigella vaccine candidate to LimmaTech Biologics, giving the Swiss biotech rights to further develop and eventually commercialize the quadrivalent bioconjugate investigational vaccine, LimmaTech is aiming to complete the Phase I/II clinical trial for this quadrivalent candidate and post data from this study within the year.
 In November 2020, Eveliqure announced the publication of key preclinical data for its clinical-stage vaccine candidate against Shigellosis and ETEC.
Why Purchase the Report?
• To visualize the global shigella vaccine pipeline market segmentation-based vaccine type, age group, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous shigella vaccine pipeline market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key vaccines of all the major players.
The global shigella vaccines pipeline market report would provide approximately 46 tables, 56 figures, and 165 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Vaccine Type
3.2. Snippet by Age Group
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Emerging pipeline vaccines
4.1.2. Restraints
4.1.2.1. Side effects associated with the vaccines
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Vaccine Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
7.1.2. Market Attractiveness Index, By Vaccine Type
7.2. Live Attenuated Vaccines *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Inactivated Vaccines
7.4. Whole-cell inactivated vaccines
7.5. Subunit inactivated vaccines
7.6. Conjugate Vaccines
7.7. Others
8. By Age Group
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Infants *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Children
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Non-Governmental Organizations (NGOs)
9.5. Vaccination Centers
9.6. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. LimmaTech Biologics AG
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Eveliqure Biotechnologies GmbH
12.3. Zhi Fei Biological
12.4. Vaxcyte
12.5. Inventprise (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

LimmaTech Biologics AG, 4.	Key Developments, Eveliqure Biotechnologies GmbH, Zhi Fei Biological, Vaxcyte

표 목록 (Tables)

List of Tables

Table 1 Global Shigella Vaccines Pipeline Market Value, By Vaccine Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Shigella Vaccines Pipeline Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Shigella Vaccines Pipeline Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Shigella Vaccines Pipeline Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Shigella Vaccines Pipeline Market Value, By Vaccine Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Shigella Vaccines Pipeline Market Value, By Vaccine Type, 2021-2030 (US$ Million)

Table 7 Global Shigella Vaccines Pipeline Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Shigella Vaccines Pipeline Market Value, By Age Group, 2021-2030 (US$ Million)

Table 9 Global Shigella Vaccines Pipeline Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Shigella Vaccines Pipeline Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global Shigella Vaccines Pipeline Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Shigella Vaccines Pipeline Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Shigella Vaccines Pipeline Market Value, By Vaccine Type, 2021-2030 (US$ Million)

Table 14 North America Shigella Vaccines Pipeline Market Value, By Age Group, 2021-2030 (US$ Million)

Table 15 North America Shigella Vaccines Pipeline Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America Shigella Vaccines Pipeline Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Shigella Vaccines Pipeline Market Value, By Vaccine Type, 2021-2030 (US$ Million)

Table 18 South America Shigella Vaccines Pipeline Market Value, By Age Group, 2021-2030 (US$ Million)

Table 19 South America Shigella Vaccines Pipeline Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America Shigella Vaccines Pipeline Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Shigella Vaccines Pipeline Market Value, By Vaccine Type, 2021-2030 (US$ Million)

Table 22 Europe Shigella Vaccines Pipeline Market Value, By Age Group, 2021-2030 (US$ Million)

Table 23 Europe Shigella Vaccines Pipeline Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe Shigella Vaccines Pipeline Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Shigella Vaccines Pipeline Market Value, By Vaccine Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Shigella Vaccines Pipeline Market Value, By Age Group, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Shigella Vaccines Pipeline Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Shigella Vaccines Pipeline Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Shigella Vaccines Pipeline Market Value, By Vaccine Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Shigella Vaccines Pipeline Market Value, By Age Group, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Shigella Vaccines Pipeline Market Value, By End User, 2021-2030 (US$ Million)

Table 32 LimmaTech Biologics AG: Overview

Table 33 LimmaTech Biologics AG: Product Portfolio

Table 34 LimmaTech Biologics AG: Key Developments

Table 35 Eveliqure Biotechnologies GmbH: Overview

Table 36 Eveliqure Biotechnologies GmbH: Product Portfolio

Table 37 Eveliqure Biotechnologies GmbH: Key Developments

Table 38 Zhi Fei Biological: Overview

Table 39 Zhi Fei Biological: Product Portfolio

Table 40 Zhi Fei Biological: Key Developments

Table 41 Vaxcyte: Overview

Table 42 Vaxcyte: Product Portfolio

Table 43 Vaxcyte: Key Developments

Table 44 Inventprise: Overview

Table 45 Inventories: Product Portfolio

Table 46 Inventories: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 2 Global Shigella Vaccines Pipeline Market Share, By Vaccine Type, 2022 & 2030 (%)

Figure 3 Global Shigella Vaccines Pipeline Market Share, By Age Group, 2022 & 2030 (%)

Figure 4 Global Shigella Vaccines Pipeline Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global Shigella Vaccines Pipeline Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Shigella Vaccines Pipeline Market Y-o-Y Growth, By Vaccine Type, 2022-2030 (%)

Figure 7 Live Attenuated Vaccines Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 8 Inactivated Vaccines Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 9 Whole-cell inactivated vaccines Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 10 Subunit inactivated vaccines Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 11 Conjugate Vaccines Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 12 Others Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 13 Global Shigella Vaccines Pipeline Market Y-o-Y Growth, By Age Group, 2022-2030 (%)

Figure 14 Infants Age Group in Global Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 15 Children Age Group in Global Shigella Vaccines Pipeline Market Value, 2021-2030 (US Million)

Figure 16 Global Shigella Vaccines Pipeline Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 17 Hospitals End User in Global Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 18 Clinics End User in Global Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 19 Non-Governmental Organizations (NGOs) End User in Global Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 20 Vaccination Centers End User in Global Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 21 Others End User in Global Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 22 Global Shigella Vaccines Pipeline Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 24 Asia-Pacific Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 25 Europe Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 26 South America Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 27 Middle East and Africa Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 28 North America Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 29 North America Shigella Vaccines Pipeline Market Share, By Vaccine Type, 2022 & 2030 (%)

Figure 30 North America Shigella Vaccines Pipeline Market Share, By Age Group, 2022 & 2030 (%)

Figure 31 North America Shigella Vaccines Pipeline Market Share, By End User, 2022 & 2030 (%)

Figure 32 North America Shigella Vaccines Pipeline Market Share, By Country, 2022 & 2030 (%)

Figure 33 South America Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 34 South America Shigella Vaccines Pipeline Market Share, By Vaccine Type, 2022 & 2030 (%)

Figure 35 South America Shigella Vaccines Pipeline Market Share, By Age Group, 2022 & 2030 (%)

Figure 36 South America Shigella Vaccines Pipeline Market Share, By End User, 2022 & 2030 (%)

Figure 37 South America Shigella Vaccines Pipeline Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 39 Europe Shigella Vaccines Pipeline Market Share, By Vaccine Type, 2022 & 2030 (%)

Figure 40 Europe Shigella Vaccines Pipeline Market Share, By Age Group, 2022 & 2030 (%)

Figure 41 Europe Shigella Vaccines Pipeline Market Share, By End User, 2022 & 2030 (%)

Figure 42 Europe Shigella Vaccines Pipeline Market Share, By Country, 2022 & 2030 (%)

Figure 43 Asia-Pacific Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 44 Asia-Pacific Shigella Vaccines Pipeline Market Share, By Vaccine Type, 2022 & 2030 (%)

Figure 45 Asia-Pacific Shigella Vaccines Pipeline Market Share, By Age Group, 2022 & 2030 (%)

Figure 46 Asia-Pacific Shigella Vaccines Pipeline Market Share, By End User, 2022 & 2030 (%)

Figure 47 Asia-Pacific Shigella Vaccines Pipeline Market Share, By Country, 2022 & 2030 (%)

Figure 48 Middle East & Africa Shigella Vaccines Pipeline Market Value, 2021-2030 (US$ Million)

Figure 49 Middle East & Africa Shigella Vaccines Pipeline Market Share, By Vaccine Type, 2022 & 2030 (%)

Figure 50 Middle East & Africa Shigella Vaccines Pipeline Market Share, By Age Group, 2022 & 2030 (%)

Figure 51 Middle East & Africa Shigella Vaccines Pipeline Market Share, By End User, 2022 & 2030 (%)

Figure 52 LimmaTech Biologics AG: Financials

Figure 53 Eveliqure Biotechnologies GmbH: Financials

Figure 54 Zhi Fei Biological: Financials

Figure 55 Vaxcyte: Financials

Figure 56 Inventories: Financials

세계 이질균 백신 시장 – 2023-2030

Global Shigella Vaccines Market - 2023-2030